Hematologic Oncology

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses long-term data from avapritinib in advanced systemic mastocytosis from the PATHFINDER trial.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

Nathan Denlinger, DO, discusses real-world data with second-line liso-cel and axi-cel in patients with relapsed/refractory large B-cell lymphoma.

Fernando Gibran-Nunes, MD, highlights findings from a meta-analysis investigating the efficacy and safety of loncastuximab tesirine in pretreated DLBCL.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

Peter Riedell, MD, discussed the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma.

Adoptive cell therapy elicited MRD-negative responses with low rates of GVHD and neurotoxicities in adult patients with high-risk B-ALL.

The FDA updated axi-cel labeling to remove the limitation of use for patients with relapsed or refractory primary central nervous system lymphoma.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

Ustekinumab plus prophylaxis did not reduce acute GVHD in patients who underwent HCT from matched unrelated donors.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

Tagraxofusp was well tolerated and yielded modest efficacy signals as monotherapy in myelofibrosis.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

Dr Phillips discusses updated data from the EPCORE NHL-1 trial investigating epcoritamab monotherapy in patients with relapsed/refractory LBCL.

The FDA has approved a 375-mg vial of nelarabine for intravenous administration in both T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Sofi-cel has received FDA breakthrough therapy designation for heavily pretreated patients with relapsed/refractory T-ALL and T-LBL.

The FDA has granted fast track designation to gamgertamig for autoimmune hemolytic anemia and immune thrombocytopenia.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

Dr Falchi discusses why the FDA approval of epcoritamab plus lenalidomide/rituximab is clinically meaningful for relapsed/refractory follicular lymphoma.

Lindsay AM Rein, MD, discusses the TSS assessment from the SUMMIT trial investigating bezuclastinib in adult patients with non-advanced SM.